Baculovirus Expression Vector System
Our research team devoted to making us the world leader in BEVS technology.
PSC utilizes a proprietary Baculovirus Expression Vector System (BEVS) for development of all its products and services. The platform leverages a natural infection process of insect cells with an engineered baculovirus that specifically infects and re-programs the insect cell to produce the recombinant protein(s) desired.
The BEVS platform utilized at PSC has the following advantages:
- Patented, Serum Free, Suspension Growing Cell line
- High Production Levels
- Recombinant Products are Correctly Folded – Important for Large Complex Proteins/Antigens
- cGMP Qualified Master Virus Banks
- cGMP Qualified Cell Line (expresSF+® Cells)
- Safety – Extensive Clinical Use and Regulatory History
- Three products in Phase III Development and Approaching Licensure
- Diamyd® - Diamyd Medical
- FluBlok® – Protein Sciences Corporation
- Glybera – Amsterdam Molecular Therapeutics (AMT)
- Knowledge of Fed-Batch and Fermentation at Higher Cell Densities
